AMBRISENTAN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H22N2O4
Molecular Weight	378.4211
Optical Activity	( + )
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC([C@H](OC1=NC(C)=CC(C)=N1)C(O)=O)(C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=OUJTZYPIHDYQMC-LJQANCHMSA-N

InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C22H22N2O4
Molecular Weight	378.4211
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022081s029lbl.pdf

Ambrisentan (alternative Names: BSF 208075; GSK 1325760; GSK1325760A; Letairis) is an endothelin receptor antagonist that is selective for the endothelin type-A (ETA) receptor. The chemical name of ambrisentan is (+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid. Ambrisentan is indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. As an endothelin receptor antagonist, ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure. Endothelin-1 (ET-1) is a potent autocrine and paracrine peptide. Two receptor subtypes, ETA and ETB, mediate the effects of ET-1 in the vascular smooth muscle and endothelium. The primary actions of ETA are vasoconstriction and cell proliferation, while the predominant actions of ETB are vasodilation, antiproliferation, and ET-1 clearance. In patients with PAH, plasma ET-1 concentrations are increased as much as 10-fold and correlate with increased mean right atrial pressure and disease severity. ET-1 and ET-1 mRNA concentrations are increased as much as 9-fold in the lung tissue of patients with PAH, primarily in the endothelium of pulmonary arteries. These findings suggest that ET-1 may play a critical role in the pathogenesis and progression of PAH. Ambrisentan is a high-affinity (Ki=0.011 nM) ETA receptor antagonist with a high selectivity for the ETA versus ETB receptor (>4000-fold). The clinical impact of high selectivity for ETA is not known.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Endothelin receptor ET-B 11 Target ID: CHEMBL1785 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19920913	Antagonist 2849
Endothelin receptor ET-A 22 Target ID: CHEMBL252 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19920913	Antagonist 2849		0.011 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pulmonary arterial hypertension 36 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022081s029lbl.pdf	Primary		Approved 8583	LETAIRIS Approved Use Letairis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): To improve exercise ability and delay clinical worsening. In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability [see Clinical Studies (14.2) Launch Date 2007

C_max

Value	Dose	Co-administered	Analyte	Population
838.3 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19455620	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		AMBRISENTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
6976.5 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19455620	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		AMBRISENTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
9 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022081s033lbl.pdf	steady-state, oral		AMBRISENTAN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
18.9 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/19455620	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		AMBRISENTAN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
10 mg 1 times / day multiple, oral Highest studied dose Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022081s000_LBL.pdf https://pubmed.ncbi.nlm.nih.gov/22506623	unhealthy, 45.6 years Health Status: unhealthy Age Group: 45.6 years Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022081s000_LBL.pdf https://pubmed.ncbi.nlm.nih.gov/22506623	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022081s000_LBL.pdf https://pubmed.ncbi.nlm.nih.gov/22506623
100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022081s000_LBL.pdf	healthy, adult Health Status: healthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022081s000_LBL.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022081s000_LBL.pdf
5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022081s000_LBL.pdf	pregnant, adult Health Status: pregnant Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022081s000_LBL.pdf	Other AEs: Fetal damage... Other AEs: Fetal damage (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022081s000_LBL.pdf
5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022081s000_LBL.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022081s000_LBL.pdf	Other AEs: Liver injury... Other AEs: Liver injury (serious) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022081s000_LBL.pdf
5 mg 1 times / day multiple, oral Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02080637	unhealthy, children Health Status: unhealthy Age Group: children Sources: https://clinicaltrials.gov/ct2/show/NCT02080637	Other AEs: Anemia, Hypertension... Other AEs: Anemia (below serious, 2 patients) Hypertension (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT02080637
10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00768300	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT00768300	Other AEs: Anaemia, Acute myocardial infarction... Other AEs: Anaemia (serious, 1 patient) Acute myocardial infarction (serious, 3 patients) Angina pectoris (serious, 1 patient) Angina unstable (serious, 1 patient) Atrial fibrillation (serious, 2 patients) Sinus tachycardia (serious, 1 patient) Cardiac failure congestive (serious, 4 patients) Cardiomegaly (serious, 1 patient) Dilatation atrial (serious, 1 patient) Tricuspid valve incompetence (serious, 1 patient) Palpitations (serious, 1 patient) Extrasystoles (serious, 1 patient) Electromechanical dissociation (serious, 1 patient) Acute vestibular syndrome (serious, 1 patient) Visual impairment (serious, 1 patient) Constipation (serious, 4 patients) Nausea (serious, 2 patients) Colonic polyp (serious, 1 patient) Small intestinal obstruction (serious, 1 patient) Upper gastrointestinal haemorrhage (serious, 1 patient) Oedema peripheral (serious, 4 patients) Oedema (serious, 1 patient) Pain (serious, 2 patients) Pyrexia (serious, 2 patients) Fatigue (serious, 2 patients) Catheter site haemorrhage (serious, 1 patient) Influenza like illness (serious, 1 patient) Hyperthermia (serious, 1 patient) Pharyngitis (serious, 1 patient) Sinusitis (serious, 1 patient) Pneumonia (serious, 9 patients) Bronchitis (serious, 3 patients) Bronchopneumonia (serious, 1 patient) Infection (serious, 1 patient) Cellulitis (serious, 2 patients) Sepsis (serious, 2 patients) Influenza (serious, 2 patients) Urinary tract infection (serious, 1 patient) Oral candidiasis (serious, 1 patient) Conjunctivitis viral (serious, 1 patient) Road traffic accident (serious, 1 patient) Fracture rib (serious, 1 patient) Electrocardiogram ST-T segment abnormal (serious, 1 patient) Electrocardiogram T wave inversion (serious, 1 patient) Computerised tomogram thorax abnormal (serious, 1 patient) Hyperkalaemia (serious, 4 patients) Hypokalaemia (serious, 2 patients) Hyperglycaemia (serious, 2 patients) Anorexia (serious, 1 patient) Diabetic ketoacidosis (serious, 1 patient) Hypophosphataemia (serious, 1 patient) Back pain (serious, 1 patient) Musculoskeletal pain (serious, 1 patient) Clubbing (serious, 1 patient) Pain in jaw (serious, 1 patient) Myalgia (serious, 1 patient) Squamous cell carcinoma (serious, 1 patient) Prostate cancer (serious, 1 patient) Prostate cancer metastatic (serious, 1 patient) Lung neoplasm malignant (serious, 1 patient) Headache (serious, 5 patients) Cerebrovascular accident (serious, 1 patient) Ischaemic stroke (serious, 1 patient) Somnolence (serious, 1 patient) Carotid artery stenosis (serious, 1 patient) Coma (serious, 1 patient) Grand mal convulsion (serious, 1 patient) Nerve compression (serious, 1 patient) Hypoaesthesia (serious, 1 patient) Anxiety (serious, 3 patients) Delirium (serious, 1 patient) Insomnia (serious, 1 patient) Renal failure acute (serious, 2 patients) Renal failure (serious, 1 patient) Benign prostatic hyperplasia (serious, 1 patient) Idiopathic pulmonary fibrosis (serious, 20 patients) Emphysema (serious, 2 patients) Pulmonary fibrosis (serious, 2 patients) Pulmonary alveolar haemorrhage (serious, 1 patient) Dyspnoea (serious, 17 patients) Respiratory arrest (serious, 1 patient) Cough (serious, 4 patients) Haemoptysis (serious, 4 patients) Productive cough (serious, 1 patient) Acute respiratory failure (serious, 5 patients) Respiratory failure (serious, 4 patients) Nasal congestion (serious, 4 patients) Allergic rhinitis (serious, 1 patient) Choking (serious, 1 patient) Rhinorrhoea (serious, 1 patient) Hypoxia (serious, 1 patient) Pneumothorax (serious, 1 patient) Pneumonitis (serious, 1 patient) Hiccups (serious, 1 patient) Pleurisy (serious, 1 patient) Hypotension (serious, 4 patients) Hypertension (serious, 3 patients) Subclavian vein thrombosis (serious, 1 patient) Flushing (serious, 1 patient) Hot flush (serious, 1 patient) Cardiac ventricular disorder (serious, 1 patient) Peripheral ischaemia (serious, 1 patient) Oedema peripheral (below serious, 73 patients) Upper respiratory tract infection (below serious, 47 patients) Headache (below serious, 47 patients) Dyspnoea (below serious, 40 patients) Nasopharyngitis (below serious, 37 patients) Idiopathic pulmonary fibrosis (below serious, 19 patients) Nasal congestion (below serious, 27 patients) Diarrhoea (below serious, 20 patients) Sinusitis (below serious, 20 patients) Back pain (below serious, 18 patients) Dizziness (below serious, 20 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00768300
10 mg 1 times / day steady, oral Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02290613	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT02290613	Other AEs: Jaw fracture, Edema... Other AEs: Jaw fracture (serious, 1 patient) Edema (below serious, 8 patients) Diarrhea (below serious, 4 patients) Paraesthesia (below serious, 4 patients) Epistaxis (below serious, 3 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT02290613

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	inhibitor 2438

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OATP1B1 1079 OATP1B3 961 NTCP 39 BSEP 550 BCRP 910 P-gp 1741 MRP2 499 CYP2A6 879 CYP2C8 1057 UGT1A1 246 UGT1A6 136 UGT1A9 148 UGT2B7 197	P-gp 2052 CYP2C19 1119 UGT1A9 423 UGT2B7 456 UGT1A3 470 OATP1B1 503 MRP2 252 BSEP 63 CYP3A5 446	NTCP 2 BSEP 8 MRP2 146

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022081s041lbl.pdf Page: 12.0	no
BSEP 554	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 36.0	no
BSEP 554	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 36.0	no
MRP2 625	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 36.0	no
MRP2 625	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 36.0	no
NTCP 40	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 36.0	no
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 36, 61	no	no (co-administration study) Comment: ambrisentan had no inhibitory effect on the P-gp efflux of digoxin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 36, 61
NTCP 40	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 36.0	weak [IC50 100 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022081s041lbl.pdf Page: 12.0	weak [IC50 45 uM]
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022081s041lbl.pdf Page: 12.0	weak [IC50 47 uM]
UGT1A1 303	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 10, 55	weak [Inhibition 300 uM]
UGT1A6 171	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 10, 55	weak [Inhibition 300 uM]
UGT1A9 155	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 10, 55	weak [Inhibition 300 uM]
UGT2B7 210	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 10, 55, 64	weak [Inhibition 300 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_ClinPharmR_P1.pdf Page: 23.0	weak
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_ClinPharmR_P1.pdf Page: 23.0	weak
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_ClinPharmR_P1.pdf Page: 23.0	weak

Drug as victim

Target	Modality	Activity
BSEP 63	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 61.0	likely
MRP2 252	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 61.0	likely
CYP2C19 1119	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 9.0	yes
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 9.0	yes
CYP3A5 446	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 9.0	yes
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022081s041lbl.pdf Page: 12.0	yes
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 61.0	yes
UGT1A3 470	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 9.0	yes
UGT1A9 423	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 9.0	yes
UGT2B7 456	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022081s000_PharmR_P1.pdf Page: 9.0	yes

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA0024ZZ	http://www.aablocks.com/goods/Goods/detail?id=AA0024ZZ
Aaron Chemicals	AR0025RR	http://www.aaronchem.com/177036-94-1
abcr GmbH	AB436215	http://www.abcr.com/shop/en/AB436215
Achemtek	0102-012312	http://www.achemtek.com/177036-94-1
Acorn PharmaTech	ACN-030051	http://www.acornpharmatech.com/
Adooq BioScience	A11291	https://www.adooq.com/ambrisentan.html
AEchem Scientific Corp., USA	AE024026	http://www.aechemsc.com/info_products/AE024026.php
AK Scientific, Inc. (AKSCI)	66500	http://www.aksci.com/item_detail.php?cat=66500
Alsachim	1485	http://www.alsachim.com/product-C2081-glo.bal-view.html
Anward	ANW-59416	http://www.anward.com/pro_result/45867
ApexBio Technology	B2075	http://www.apexbt.com/ambrisentan-26523.html
AstaTech, Inc.	FD7219	http://www.astatechinc.com/CPSResult.php?CRNO=37302
Aurora Fine Chemicals LLC	A24.076.624	http://online.aurorafinechemicals.com/info?ID=A24.076.624
Aurum Pharmatech LLC	K-5435	http://www.Aurumpharmatech.com/Product/ProductDetails/K_5435
AvaChem Scientific	2664	http://www.avachem.com/productSearch.asp?2664
Axon MedChem	1648	https://www.axonmedchem.com/product/1648
BioSynth	J-519579	https://www.biosynth.com/en/products/all-products/products/J-519579.html
BLD Pharm	BD118907	http://www.bldpharm.com/products/177036-94-1.html
Boerchem	BC224510	http://www.boerchem.com/?product_37829.html
Capot Chemical	18318	http://www.capotchem.com/en/18318.htm
Capot Chemical	PubChem18318	http://www.capotchem.com/en/18318.htm
Chem Scene	CS-0447	http://www.chemscene.com/177036-94-1.html
ChemMol	30114223	http://www.chemmol.com/chemmol/30114223.html
ChemMol	44007214	http://www.chemmol.com/chemmol/44007214.html
Chemspace	CSSB00015191759	https://chem-space.com/CSSB00015191759
Clearsynth	CS-O-00462	https://www.clearsynth.com/en/CSO00462.html
CSNpharm	CSN10496	https://www.csnpharm.com/products/ambrisentan.html
eNovation Chemicals	K09791	https://www.enovationchem.com/ProductDetails.asp?ProductID=K09791
Excenen	EX-A3315	https://www.excenen.com/searchresultlist.php?id=177036-94-1
Hairui	HR136588	http://www.hairuichem.com/en/product/177036-94-1.html
iChemical	EBD31205	http://www.ichemical.com/products/177036-94-1.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN00130941	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00130941
LGC Standards	MM3756.00-0250	https://www.lgcstandards.com/US/en/p/MM3756.00-0250
Matrix Scientific	149338	https://www.matrixscientific.com/149338.html
MedChem Express	HY-13209	https://www.medchemexpress.com/Ambrisentan.html
Oakwood	221767	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=102766&ExtHyperLink=1
Smolecule	S518340	http://www.smolecule.com/products/s518340
Synblock Inc	SB17358	http://www.synblock.com/product/177036-94-1.html
TCI (Tokyo Chemical Industry)	A2966	http://www.tcichemicals.com/eshop/en/us/commodity/A2966/index.html
THE BioTek	bt-258891	https://www.thebiotek.com/product/inhibitors/bt-258891
Tocris	5828	https://www.tocris.com/products/ambrisentan_5828
TripleBond	CA0131	http://www.triplebond-canada.com/prod/1093/
VladaChem	VL279151-25MG	https://www.vladachem.com/product.php?products=177036-94-1
Yuhao Chemical	JZ1234	http://www.chemyuhao.com/177036-94-1.html

PubMed

Title	Date	PubMed
Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis.	2010-01-29	20113497
[Endothelin receptor antagonists - their role in pulmonary medicine].	2009-12	20032843
Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease.	2009-12	19775299
No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.	2009-12	19455620
Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.	2009-11-17	19909879
Gateways to clinical trials.	2009-11	20094643
Safety and tolerability of bosentan in the management of pulmonary arterial hypertension.	2009-09-21	19920927
Gateways to clinical trials.	2009-09	19907722
Can we improve outcome of congenital diaphragmatic hernia?	2009-09	19669650
Use of inhaled iloprost in an infant with bronchopulmonary dysplasia and pulmonary artery hypertension.	2009-08	19949642
Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.	2009-08	19601701
Gateways to clinical trials.	2009-06	19649342
Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.	2009-06	19517317
Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.	2009-06	19487219
Effect of ketoconazole on the pharmacokinetic profile of ambrisentan.	2009-06	19389876
The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers.	2009-05	19552747
Ambrisentan: new drug. Too risky in mildly symptomatic pulmonary hypertension.	2009-04	19585715
Gateways to clinical trials.	2009-04	19536362
New concepts in the invasive and non invasive evaluation of remodelling of the right ventricle and pulmonary vasculature in pulmonary arterial hypertension.	2009-03-12	19452037
Ambrisentan for the treatment of pulmonary arterial hypertension.	2009-02-06	19920913
A meta-analysis of randomized controlled trials in pulmonary arterial hypertension.	2009-02	19155250
Pulmonary arterial hypertension in children: a medical update.	2009-01	19391006
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.	2009-01	18812445
Therapeutic methods used in patients with Eisenmenger syndrome.	2009	19950085
Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model.	2009	19715380
Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.	2009	19688101
Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.	2009	19558194
Treatment of pediatric pulmonary hypertension.	2009	19554091
Endothelin-1 inhibition by ambrisentan as a potential treatment adjunct after debulking surgery in epithelial ovarian cancer.	2009	19544975
Review of inhaled iloprost for the control of pulmonary artery hypertension in children.	2009	19436672
[Pulmonary arterial hypertension: a voyage around the year 2008].	2009	19303531
Ambrisentan and its role in the management of pulmonary arterial hypertension.	2008-12	19198697
Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers.	2008-12	18832294
Role of ambrisentan in the management of pulmonary hypertension.	2008-11	18957622
[Specific drugs for the treatment of pulmonary arterial hypertension - current status].	2008-10	18814092
Pulmonary arterial hypertension: on the way to a manageable disease.	2008-09	18729002
[Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment].	2008-08	18942347
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?	2008-08	18562303
The status of pulmonary arterial hypertension in 2008.	2008-06-10	18541751
Ambrisentan for the management of pulmonary arterial hypertension.	2008-05	18555930
[Systemic sclerosis].	2008-05	18552072
Gateways to clinical trials.	2008-03	18560631
Acute right ventricular failure in the setting of acute pulmonary embolism or chronic pulmonary hypertension: a detailed review of the pathophysiology, diagnosis, and management.	2008-02	19924277
Pulmonary hypertension: past, present and future.	2008-01	19561874
Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.	2008	19183742
Ambrisentan.	2008	18840007
Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.	2008	18681488
Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in experimental pulmonary hypertension.	2008	18612919
Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.	2008	18533738
Ambrisentan for pulmonary arterial hypertension.	2005-07	19804142

Patents

Sample Use Guides

In Vivo Use Guide

5 mg once daily, and consider increasing the dose to 10 mg once daily if 5 mg is tolerated. Tablets may be administered with or without food.

Route of Administration: Oral

In Vitro Use Guide

The effect of the novel and ET(A) receptor selective antagonist LU 208075 (AMBRISENTAN) was characterized by the contraction and relaxation induced by ET-1 and bigET-1 on rat basilar artery. Concentration-effect curves were constructed by cumulative application of ET-1 or bigET-1 in the presence of LU 208075 (10(-7)M, 10(-6)M, and 10(-5)M). The effect of LU 208075 was determined by the pA(2) value. The contraction by ET-1 and bigET-1 was inhibited by LU 208075 in a dose-dependent manner.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:16:52 GMT 2025` Edited by `admin` on `Wed Apr 02 09:16:52 GMT 2025`
Record UNII	HW6NV07QEC
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VOLIBRIS

Preferred Name

English

AMBRISENTAN

Official Name

English

AMBRISENTAN [MI]

Common Name

English

(+)-(2S)-2-((4,6-DIMETHYLPYRIMIDIN-2-YL)OXY)-3-METHOXY-3,3-DIPHENYLPROPANOIC ACID

Systematic Name

English

AMBRISENTAN [JAN]

Common Name

English

GSK1325760

Code

English

AMBRISENTAN [ORANGE BOOK]

Common Name

English

GSK-1325760

Code

English

LU-208075

Code

English

LETAIRIS

Brand Name

English

AMBRISENTAN [MART.]

Common Name

English

GSK1325760A

Code

English

ambrisentan [INN]

Common Name

English

AMBRISENTAN [EMA EPAR]

Common Name

English

Ambrisentan [WHO-DD]

Common Name

English

GSK-1325760A

Code

English

AMBRISENTAN [VANDF]

Common Name

English

AMBRISENTAN, (+)-

Common Name

English

Classification Tree Code System Code

WHO-ATC

C02KX52